P
59.22
0.63 (1.08%)
| Previous Close | 58.59 |
| Open | 60.05 |
| Volume | 797,979 |
| Avg. Volume (3M) | 815,529 |
| Market Cap | 3,684,154,368 |
| Price / Earnings (TTM) | 81.12 |
| Price / Earnings (Forward) | 26.39 |
| Price / Sales | 18.07 |
| Price / Book | 5.44 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 27.04% |
| Operating Margin (TTM) | -68.18% |
| Diluted EPS (TTM) | 0.780 |
| Quarterly Revenue Growth (YOY) | -88.90% |
| Quarterly Earnings Growth (YOY) | 381.70% |
| Total Debt/Equity (MRQ) | 1.65% |
| Current Ratio (MRQ) | 17.25 |
| Operating Cash Flow (TTM) | 336.94 M |
| Levered Free Cash Flow (TTM) | 327.76 M |
| Return on Assets (TTM) | 2.48% |
| Return on Equity (TTM) | 8.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Protagonist Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.10% |
| % Held by Institutions | 108.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 30 Jun 2025 | 6,172,006 |
| Rtw Investments, Lp | 30 Jun 2025 | 5,756,277 |
| Deep Track Capital, Lp | 30 Jun 2025 | 3,245,899 |
| Bvf Inc/Il | 30 Jun 2025 | 3,211,041 |
| Johnson & Johnson | 30 Jun 2025 | 2,449,183 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2025 | 1,092,262 |
| Commodore Capital Lp | 30 Jun 2025 | 1,075,000 |
| Perceptive Advisors Llc | 30 Jun 2025 | 1,074,448 |
| Adar1 Capital Management, Llc | 30 Jun 2025 | 948,069 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 73.00 (Leerink Partners, 23.27%) | Buy |
| Median | 72.00 (21.58%) | |
| Low | 69.00 (JMP Securities, 16.52%) | Buy |
| Average | 71.33 (20.45%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 56.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 17 Sep 2025 | 72.00 (21.58%) | Buy | 59.22 |
| Leerink Partners | 12 Sep 2025 | 73.00 (23.27%) | Buy | 58.86 |
| JMP Securities | 07 Aug 2025 | 69.00 (16.51%) | Buy | 50.96 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |